false
0001642380
0001642380
2026-06-11
2026-06-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 11, 2026
Insight
Molecular Diagnostics Inc.
(Exact
name of Registrant as specified in its charter)
| California |
|
1-37648 |
|
27-1041563 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
No.) |
|
(IRS
Employer
Identification
No.) |
2
International Plaza Dr., Suite 510
Nashville,
Tennessee 37217
(Address
of principal executive offices) (Zip code)
(615)
255-8880
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
Registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
stock, no par value |
|
IMDX |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
As
reported below under Item 5.07 of this report, Insight Molecular Diagnostics Inc. (the “Company”) held its 2026 Annual Meeting
of Shareholders (the “Annual Meeting”) on June 11, 2026, at which the Company’s shareholders approved an amendment
to the Company’s Amended and Restated 2018 Equity Incentive Plan (as previously amended, the “Incentive Plan”) to provide
for an additional 1,750,000 shares of the Company’s common stock to be available for the issuance of equity awards thereunder,
such that the total number of shares of common stock authorized for issuance under the Incentive Plan is 5,550,000 shares of common stock.
For
more information about the Incentive Plan, see the Company’s definitive proxy statement on Schedule 14A relating to the Annual
Meeting, which was originally filed with the Securities and Exchange Commission on April 30, 2026 (the “Proxy Statement”),
the relevant portions of which are incorporated herein by reference. The foregoing description of the amendment to the Incentive Plan
does not purport to be complete and is qualified in its entirety by reference to the complete text of the amendment to the Incentive
Plan, a copy of which is filed as Exhibit 10.1 to this report and is incorporated by reference herein.
Item
5.07. Submission of Matters to a Vote of Security Holders.
General
The
Annual Meeting was held on June 11, 2026, virtually via live webcast at https://edge.media-server.com/mmc/p/k94peovi. Present
at the Annual Meeting virtually or by proxy were holders of 23,954,212 shares of common stock of the Company, which represented 74.19%
of the voting power of all shares of common stock of the Company as of April 27, 2026, the record date for the Annual Meeting.
Proposals
The
shareholders of the Company voted on the following proposals at the Annual Meeting, as more fully described in the Proxy Statement:
| |
1. |
To
elect the following four (4) director nominees, each to serve until the 2027 annual meeting of shareholders and until his successor
has been elected and qualified, or until his earlier death, resignation, or removal: Joshua Riggs, Andrew Arno, Andrew J. Last and
Louis E. Silverman; |
| |
2. |
To
ratify the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the year ending
December 31, 2026; |
| |
3. |
To
approve, on a non-binding advisory basis, the Company’s named executive officer compensation for the year ended December 31,
2025; and |
| |
4. |
To
approve an amendment to the Incentive Plan to increase the total number of shares of the Company’s common stock authorized
for issuance under the Incentive Plan by 1,750,000, to a total of 5,550,000 shares. |
Voting
Results
The
final voting results for each of these proposals at the Annual Meeting are detailed below.
1.
Election of Directors
| | |
| | |
Shares Voted | |
| Director Nominee | |
For | | |
Against | | |
Abstained | | |
Broker Non-Votes | |
| Joshua Riggs | |
| 19,239,253 | | |
| 2,420 | | |
| 3,820 | | |
| 4,708,719 | |
| Andrew Arno | |
| 19,100,993 | | |
| 140,445 | | |
| 4,056 | | |
| 4,708,719 | |
| Andrew J. Last | |
| 19,237,621 | | |
| 3,938 | | |
| 3,935 | | |
| 4,708,719 | |
| Louis E. Silverman | |
| 19,224,148 | | |
| 17,290 | | |
| 4,056 | | |
| 4,708,719 | |
Based
on the votes set forth above, each director nominee was duly elected to serve until the 2027 annual meeting of shareholders and until
his successor has been elected and qualified, or until his earlier death, resignation, or removal.
2.
Ratification of Appointment of Accounting Firm
| Shares
Voted |
| For |
|
Against |
|
Abstained |
|
Broker
Non-Votes |
| 23,949,191 |
|
2,420 |
|
2,601 |
|
0 |
Based
on the votes set forth above, the shareholders ratified the appointment of CBIZ CPAs P.C. as the Company’s independent registered
public accounting firm for the year ending December 31, 2026.
3.
Say On Pay Proposal
| Shares
Voted |
| For |
|
Against |
|
Abstained |
|
Broker
Non-Votes |
| 19,199,697 |
|
26,126 |
|
19,679 |
|
4,708,719 |
Based
on the votes set forth above, the shareholders approved, on a non-binding advisory basis, the Company’s named executive officer
compensation for the year ended December 31, 2025.
4.
Approval of Amendment to Incentive Plan
| Shares
Voted |
| For |
|
Against |
|
Abstained |
|
Broker
Non-Votes |
| 19,117,865 |
|
122,829 |
|
4,799 |
|
4,708,719 |
Based
on the votes set forth above, the shareholders approved the amendment to the Incentive Plan to increase the total number of shares of
the Company’s common stock authorized for issuance under the Incentive Plan by 1,750,000, to a total of 5,550,000 shares.
Item
9.01. Financial Statements and Exhibits
| Exhibit
No. |
|
Description |
| 10.1# |
|
Second Amendment to the Insight Molecular Diagnostics Inc. Amended and Restated 2018 Equity Incentive Plan |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
#
The referenced exhibit is a management contract, compensatory plan or arrangement.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
INSIGHT
MOLECULAR DIAGNOSTICS INC. |
| |
|
|
| Date:
June 17, 2026 |
By: |
/s/
Peter Hong |
| |
Name: |
Peter
Hong |
| |
Title: |
Vice
President, General Counsel |
